Heart failure & cardiomyopathies
Trends in mortality, heart transplantation, and left ventricular assist device use in advanced heart failure between 2003 and 2022: data from the Swedish Heart Failure Registry
Authors' conclusion
In a large nationwide cohort, all-cause and CV-mortality among AdvHFrEF patients markedly declined over the past 20 years, potentially reflecting improvements in treatments.
Study context
- Population
- Patients with advanced HFrEF in the Swedish HF Registry, 2003–202229% eligible for advanced heart failure (AdvHF) therapies
- Participants
- 5,323 patients
- Exposure
- Overall vs Eligible
- Overalln = 5,323
- Outcome
- Temporal trends in 1-year all-cause mortality (eAPC)
- Follow-up
- 1 year
Methodological detailsnationwide, Swedish HF Registry
- Nationwide
- Swedish HF Registry
Main finding
As reported in the abstract
1-year all-cause mortality, estimated annual percent change · 2003-2022
Estimated annual percent change (eAPC)
−3.8
95% CI −5.3 to −2.2
Overall
eAPC
−3.2
95% CI −6.3 to −0.1
Eligible
Observational data: associations, not effects.
Further findings
| Outcome | eAPC (95% CI) |
|---|---|
| 1-year CV mortality, estimated annual percent change · 2003-2022Overall | −4.3 (−6.0 to −2.6) |
| 1-year CV mortality, estimated annual percent change · 2003-2022Eligible | −5.6 (−9.4 to −1.7) |
Left ventricular assist devices (LVAD) and HTx use · 2003-2022
- LVAD use significantly increased
- HTx modest but non-significant rise
Original publication
Trends in mortality, heart transplantation, and left ventricular assist device use in advanced heart failure between 2003 and 2022: data from the Swedish Heart Failure Registry. Eur J Heart Fail. Published 22 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it